Related Experiment Videos
Recurrent myocardial ischemia following thrombolytic therapy: guidelines for practicing clinicians
1Thrombosis Research Center, University of Massachusetts Medical School, Worcester 01655.
Insights
Acute myocardial infarction patients treated with thrombolytic therapy face two phases: acute and subacute. The subacute phase carries risks of recurrent ischemia and reinfarction, necessitating aggressive management.
Area of Science:
- Cardiology
- Vascular Biology
- Clinical Medicine
Background:
- Acute myocardial infarction (AMI) involves plaque rupture and coronary occlusion.
- Thrombolytic therapy aims to restore blood flow, limiting initial damage.
- An underlying unstable plaque remains after thrombolysis, posing risks.
Purpose of the Study:
- To describe the two-phase natural history of AMI post-thrombolytic therapy.
- To highlight the risks of recurrent ischemic events in the subacute phase.
- To emphasize the need for aggressive diagnostic and treatment strategies.
Main Methods:
- Review of patient data and clinical outcomes following thrombolytic therapy for AMI.
- Pathological and clinical characterization of acute and subacute phases.
- Analysis of recurrent ischemia and reinfarction rates.
Main Results:
- Thrombolytic therapy successfully reperfuses most patients in the acute phase, preserving function.
- A significant percentage (20-30%) experience recurrent ischemia, and 5% reinfarction in the subacute phase.
- Elevated morbidity and mortality are observed in patients with recurrent events.
Conclusions:
- Patients treated for AMI with thrombolysis enter a subacute phase with persistent risks.
- Recurrent ischemic events significantly increase adverse outcomes.
- An aggressive approach to diagnosis and treatment is crucial for managing these high-risk patients.
Abstract:
The natural history of patients with acute myocardial infarction treated with thrombolytic therapy includes two distinct phases: the initial or acute phase is characterized pathologically by atheromatous plaque rupture and thrombotic coronary arterial occlusion, and clinically by the abrupt onset of symptoms. Prompt restoration of coronary blood flow and myocardial reperfusion during this phase, achieved in a majority of patients given thrombolytic therapy, limits myocardial necrosis, preserves ventricular function, and lowers mortality. Although the thrombus can be pharmacologically removed, an unstable anatomic substrate persists. Therefore following thrombolytic therapy, a subacute phase occurs, during which patients are at risk for recurrent ischemic events. More than a theoretical concept, experience has shown that recurrent ischemia and reinfarction develop in 20% to 30% and 5% of patients, respectively. Morbidity and mortality are elevated considerably in these patients, dictating an aggressive diagnostic and treatment approach.